Class IIOngoing
Pfizer recalls Dopamine HCl Inj
Recall date · record updated Sep 23, 2026 · Source: U.S. Food and Drug Administration (openFDA drug enforcement)
Check your product against the names and codes above. The FDA enforcement record lists the recall as voluntary: firm initiated; it does not state a consumer remedy, so follow the firm’s notice or the FDA link.
- Company
- Pfizer
- Reason
- Lack of Assurance of Sterility
- Hazard
- FDA Class II: may cause temporary or medically reversible adverse health consequences (FDA definition).
- Who’s affected
- US Nationwide.
- Where
- Nationwide
- Official notice
- www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99824…
Products
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
Codes/lots: Lot # NL5230, Exp Date:10/2027Quantity: N/ARecall no. D-0853-2026Class II
Update history
- First listed on OVERLOOKED from the official record.
When the agency expands or changes this recall, we update this page and log the change here.
Proof: raw official record (JSON) · fetched from FDA API
More Medicines & devices recalls
Medicines & devicesClass II
American Health Packaging recalls Metoclopramide Tablets
Presence of Foreign Tablets/Capsules
· FDA · Nationwide
Medicines & devicesClass II
Zydus Pharmaceuticals (USA) Inc recalls Hydrocortisone Sodium Succinate for Injection
Failed Impurities/Degradation Specifications.
· FDA · Nationwide
Medicines & devicesClass II
Teva Pharmaceuticals USA, Inc recalls Metoclopramide Tablets
Presence of Foreign Tablets/Capsules
· FDA · Nationwide